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Abstract
While cancer is relatively rare in children under 20, it is the leading cause of disease-related death 
among children aged 5 to 14 years. We aimed to describe the incidence and survival of childhood 
cancer in Oklahoma from 1997-2012. We calculated age-adjusted incidence rates and five-year 
observed survival by cancer type using Oklahoma Central Cancer Registry and Surveillance, 
Epidemiology, and End Results program data among children diagnosed with cancer under the age 
of 20 from 1997-2012. The average annual age-adjusted incidence rate of childhood cancer was 
168.9 per million for the US and 171.7 per million for Oklahoma. Overall, Oklahoma had lower 
survival from childhood cancer compared to the US (77.0% v. 80.6%). In recent years, research 
has been conducted on the epidemiology of childhood cancer. Little research has been done, 
however, on the incidence or survival of childhood cancer at state levels and none focused 
exclusively on Oklahoma.
Introduction
Cancer is relatively rare in children under 20, with an estimated 10,380 new cases in the 
United States (US) expected to be diagnosed in 2015.1 However, it is the leading cause of 
disease-related death among children aged 5 to 14 years.2 Risk factors vary by cancer type 
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and many of the proposed risk factors have limited or insufficient evidence to evaluate 
causality.3 More extensive research has been conducted on the most frequently diagnosed 
types of childhood cancers, including leukemia, lymphoma, and brain/central nervous 
system (CNS) tumors. For acute lymphocytic leukemia (ALL), known risk factors include 
age, gender, higher socioeconomic status (SES), race/ethnicity, in-utero or postnatal 
exposure to ionizing radiation, and several genetic conditions including Down syndrome. 
These factors meet most or all criteria for causality detailed in the review.3 For acute 
myeloid leukemia (AML), known risk factors are similar to those of ALL and include race/
ethnicity, previous exposure to chemotherapy agents, ionizing radiation, and several genetic 
conditions including Down syndrome.3 Ionizing radiation, stronger in AML than ALL, is the 
only established environmental risk factor for acute leukemia.4 Known risk factors for 
Hodgkin's lymphoma include family history of Hodgkin's lymphoma, Epstein-Barr virus 
infection, higher SES for older children and lower SES for younger children, along with 
fewer social contacts in early childhood.3,5,6 For childhood brain and CNS tumors, known 
risk factors are limited but include gender, therapeutic doses of ionizing radiation to the 
head, and several genetic conditions including neurofibromatosis.3,7
Until the first chemotherapy treatments were introduced in 1948 by Dr. Sydney Farber, 
known as the Father of Modern Chemotherapy, leukemia was essentially a death sentence 
with no available treatments.8,9 The survival of childhood leukemia continued to be poor 
until the 1970s, when improved treatments became available.10 Currently, the five-year 
relative survival rate of all childhood cancer is approximately 83% in the US, ranging from 
58% for some brain tumors to over 90% for Hodgkin lymphoma and retinoblastoma.11
While many studies have described the epidemiology of childhood cancer in the US,3,12,13 
this is the first in Oklahoma. The purpose of this study was to describe the differences in 
incidence and survival of cancers in Oklahoma diagnosed among children and adolescents 
under 20 years of age compared to the US from 1997 through 2012. In order to get a clearer 
understanding of both the incidence and survival of childhood cancer by race/ethnicity and 
age, we further explored the three most common types of childhood cancer: ALL, 
astrocytoma, and Hodgkin lymphoma.
Methods
Data for both incidence and survival were collected from the Oklahoma Central Cancer 
Registry (OCCR), which has collected data on cancers diagnosed in Oklahoma residents 
since January 1, 1997.14 We included children diagnosed with childhood cancer prior to 20 
years of age between 1997 and 2012 who resided in Oklahoma at the time of cancer 
diagnosis. In our analyses by cancer type, we classified cancers according to the 
International Classification of Childhood Cancers.15
We classified children by age at cancer diagnosis as <1 year of age, 1-4 years, 5-9 years, 
10-14 years, and 15-19 years. To evaluate incidence and survival by race/ethnicity, we 
classified children according to their primary race/ethnicity in the OCCR. All Oklahoma 
data are linked with Indian Health Service (IHS) records in order to decrease racial 
misclassification of American Indians/Alaska Natives (AI/AN). Due to small numbers, 
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analyses by race/ethnicity did not include Asian/Pacific Islander children. Results of this 
analysis are reported for white non-Hispanic (NH), African American NH, AI/AN NH and 
Hispanic children.
To calculate the incidence of childhood cancer in Oklahoma, we used the population 
estimates for 1997-2012 based on the US Census, resulting in average annual incidence rates 
per million for Oklahoma from 1997-2012. To age-adjust the incidence rates, we used the 
US 2000 standard million. We also calculated 95% confidence intervals (CI) for the crude 
and age-adjusted incidence rates using the formulae provided in Greenland and Rothman.16 
We calculated overall age-adjusted, age-specific, and age-adjusted race-specific incidence 
rates for the three selected childhood cancers in Oklahoma and compared these results with 
the Surveillance, Epidemiology, and End Results (SEER) estimates for childhood cancers 
from 1997-2012 using SEER*Stat software v. 8.2.1.17 To compare incidence by age and 
race/ethnicity between Oklahoma and the US, we calculated rate ratios (RR) and 95% CIs.
We calculated five-year observed survival proportions for Oklahoma children diagnosed 
between 1997 and 2008 in order to have more complete five-year follow-up through 
November 1, 2014, which was the last date of follow-up for the OCCR data. We calculated 
survival time as the time to death or the end of the study (November 1, 2014). The OCCR 
periodically conducts follow-up of those included in the registry, along with linkage with the 
Oklahoma Mortality Data, the Social Security Death Index, and the National Death Index 
(NDI) to identify those who are deceased. We used Kaplan-Meier survival analysis to 
calculate observed survival and 95% CIs at five years after diagnosis among children 0-19 
years at cancer diagnosis. The survival proportions were calculated for all age groups and 
each race/ethnicity analyzed in the incidence section. We used SEER*Stat to obtain national 
five-year observed survival proportions by age and race/ethnicity from 1997-2008 for 
comparison with Oklahoma data. However, SEER did not report survival for AI/AN separate 
from Asian/Pacific Islanders or for Hispanic children, so these results include the racial 
categories of white and African American.
We used SAS v. 9.4 for all Oklahoma analyses of incidence and survival. We used an alpha 
of 0.05 for all analyses. This study was approved by the institutional review boards at the 
University of Oklahoma Health Sciences Center and the Oklahoma State Department of 
Health.
Results
Incidence
The average annual age-adjusted incidence rate (AAIR) of childhood cancer was 168.9 per 
million for the US (95% CI: 167.0, 170.8) and 171.7 per million for Oklahoma (95% CI: 
165.4, 178.1) from 1997-2012 (Table 1). While Oklahoma AAIR of specific cancer types 
was similar to that in the US for most cancer types, there were a few differences of note. 
Oklahoma had a lower AAIR of non-Hodgkin lymphomas (excluding Burkitt lymphoma), 
other gliomas, retinoblastoma, malignant gonadal germ cell tumors (in addition to an overall 
lower AAIR of germ cell/trophoblastic tumors/neoplasms of gonads), and thyroid 
carcinomas compared to the US. However, Oklahoma had a higher AAIR for miscellaneous 
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lymphoreticular neoplasms and fibrosarcomas/peripheral nerve/other fibrous tumors 
compared to the US. Overall CNS tumors were also elevated in Oklahoma, driven primarily 
by higher AAIRs of both specified and unspecified intracranial/intraspinal neoplasms 
compared to the US. Furthermore, overall other/unspecified malignant neoplasms were 
elevated, driven by other unspecified malignant tumors in Oklahoma compared to the US.
The three most common types of cancer in Oklahoma and the US during this time were ALL 
(OK AAIR: 32.5 per million; SEER AAIR: 34.7 per million), astrocytoma (OK AAIR: 13.0 
per million; SEER AAIR: 14.0 per million), and Hodgkin lymphoma (OK AAIR: 10.8 per 
million; SEER AAIR: 12.0 per million). When evaluating each of these specific cancers by 
age, there were no significant differences between the age-specific incidence rates in 
Oklahoma and the US (Table 2). For ALL, the incidence was highest in children aged 1-4 
years and generally decreasing in older age groups. The incidence of astrocytoma was also 
higher among children aged 1-4 and 5-9 years, whereas the incidence of Hodgkin lymphoma 
increased with age, with no cases observed among children under 1 year of age in Oklahoma 
or the US. While not significant, the age-specific incidence rate for Hodgkin lymphoma in 
Oklahoma was lower for children 5-9 years and 10-14 years of age at diagnosis compared to 
the US.
Although there were no significant differences by race/ethnicity between the US and OK for 
ALL, the AAIR for AI/AN NH was 22% higher in Oklahoma than the US (95% CI: 0.90, 
1.65) (Table 3). However, the AAIR for astrocytoma was 21% lower among white children 
in Oklahoma compared to the US (RR: 0.79, 95% CI: 0.67, 0.94). Although not significant, 
the AAIR for astrocytoma for Hispanic children was 41% higher in Oklahoma compared to 
the US (RR: 1.41, 95% CI: 0.94, 2.11). In Hodgkin lymphoma, the AAIR for AI/AN NH 
children was 3.78 times greater in Oklahoma compared to the US (95% CI: 1.48, 9.67). 
Though not significantly different, the AAIR was 17% lower for white NH children (RR: 
0.83, 95% CI: 0.67, 1.02) and 50% lower for African American NH children (RR: 0.50, 95% 
CI: 0.21, 1.23), but 40% higher for Hispanic children (RR: 1.39, 95% CI: 0.76, 2.54) in 
Oklahoma compared to the US.
Survival
In Oklahoma, the five-year observed survival of all childhood cancer was 77.0% (95% CI: 
75.2%, 78.9%), which was significantly lower than the US at 80.6% (95% CI: 80.2%, 
81.0%) (Table 4). Based on 95% CIs, we observed significant differences in survival for 
certain CNS tumors, neuroblastoma, and nephroblastoma (Wilms' Tumor). While survival in 
Oklahoma was significantly lower for astrocytoma compared to the US (71.6% v. 83.1%, 
respectively), survival for other specified intracranial/intraspinal neoplasms (OK: 89.4%, 
US: 67.7%) and unspecified intracranial/intraspinal neoplasms (OK: 95.2%, US: 38.1%) was 
significantly higher in Oklahoma compared to the US. Survival for neuroblastoma (OK: 
58.4%, US: 73.6%) and Wilms' Tumor (OK: 77.4%, US: 89.1%) was also lower in 
Oklahoma compared to the US.
Patterns of survival by age differed for each cancer type, although the trends were similar 
between Oklahoma and the US with the exception of astrocytoma (Figure 1). For ALL, 
survival was lowest in children under 1 year in both Oklahoma and the US and highest 
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among children aged 1-4 and 5-9 years at diagnosis, which decreased among those 10-14 
and 15-19 years of age, with similar estimates for Oklahoma and the US. For those with 
astrocytoma, Oklahoma was similar to the US for all age groups except children aged 15-19 
years (OK: 48.7%, 95% CI: 33.0%, 64.4%; US: 76.0%, 95% CI: 72.7%, 79.3%). There were 
too few children to calculate survival for children under 1 year of age in Oklahoma. Among 
those with Hodgkin lymphoma, there were no children under 1 year of age in Oklahoma or 
the US or children from 1-4 years in Oklahoma. Among each age group, survival was near 
or greater than 90% in both Oklahoma and the US.
Regarding survival by race/ethnicity, SEER data were not available for AI/AN or Hispanic 
children for the selected diagnoses of ALL, astrocytoma, and Hodgkin lymphoma (Table 5). 
In Oklahoma, five-year observed survival for ALL was highest in Hispanic (92.0%), white 
NH (86.0%), and AI/AN NH children (82.0%), but lowest in African American NH children 
(70.8%); however, the 95% confidence intervals overlapped and were imprecise. In the US, 
the five-year observed survival for white children (regardless of Hispanic ethnicity) with 
ALL was 85.7% (95% CI: 84.9%, 86.5%) and for African American children was 80.4% 
(95% CI: 77.3%, 83.5%). Among children with astrocytoma, African American NH children 
had a five-year observed survival of 50% and Hispanic children had a survival of 62.5%, 
compared to 73.4% among white NH children and 87.5% among AI/AN NH children in 
Oklahoma. Again, the 95% CIs were imprecise and overlapped. SEER data indicated 
survival of 84.7% (95% CI: 83.3%, 86.1%) for white children and 73.5% (95% CI: 69.0%, 
78.0%) for African American NH children in the US. Among children with Hodgkin 
lymphoma in Oklahoma, survival was 83.3% for African American NH children, 91.8% for 
white NH children, 94.4% for AI/AN NH children, and 100% for Hispanic children. In 
SEER, the survival was over 94% for both white (95.9%, 95% CI: 95.1%, 96.7%) and 
African American children (94.1%, 95% CI: 91.6%, 96.6%).
Discussion
Overall, trends for incidence and survival were similar between the US and Oklahoma, with 
increases in some tumor types and decreases in others. The most striking difference was the 
higher AAIRs of other specified and unspecified intracranial/intraspinal neoplasms in 
Oklahoma compared to the US. However, the survival for these tumors was also higher in 
Oklahoma compared to the US. One possible explanation is difference in classification of 
CNS tumors in Oklahoma, but this needs further investigation to confirm. Survival from 
neuroblastoma and Wilms' Tumor were also significantly lower in Oklahoma compared to 
the US; however, these tumors are rare and the estimates were imprecise.
The incidence of Hodgkin lymphoma in Oklahoma AI/AN NH children was significantly 
higher than that in US AI/AN children based on 95% CIs. Although intended to be 
nationally representative, SEER data may not be representative of all AI/AN populations in 
the US as SEER primarily reflects the AI/AN population in New Mexico and Alaska, which 
could explain the observed difference. The Cherokee Nation Registry, located in 
Northeastern Oklahoma, is included in SEER, but not in the publicly-available files for 
analysis.18
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Although the underlying cause of ALL is unknown, there are many hypotheses as to why 
there are differences in incidence between ages and race/ethnicities. A reported age peak in 
childhood ALL occurs between ages 2 and 5, especially in white children.19 Studies have 
hypothesized that because of the young age of many children with ALL, exposure may 
occur in-utero.20-22 We observed no clear trend in the incidence of astrocytoma by age at the 
state or national levels, but Gurney, Smith, and Bunin23 reported two age peaks of 
astrocytoma; one peak around age 5 and another at age 13 using SEER data from 
1986-1994. Percy, Smith, Linet, Ries, and Friedman24 reported age as a risk factor for 
Hodgkin's lymphoma in children and both Oklahoma and U.S. data confirmed this finding. 
Percy et al.24 observed that the increased risk by age was present regardless of race/ethnicity. 
Furthermore, Cartwright and Watkins25 stated that the incidence of Hodgkin's lymphoma 
peaks during two age groups, from 15-34 and over 60 years. This trend is present in more 
developed and urbanized countries, such as the U.S., indicating a relationship with 
socioeconomic status.25
The incidence rates of both ALL and Hodgkin lymphoma were lower among African 
American compared to white children in an analysis of combined National Program of 
Cancer Registries and SEER registry data from 2001-2009.26 In a study comparing the 
incidence rates of childhood cancer for Alaska Natives to white children from SEER, Lanier 
et al.27 observed no differences for ALL or astrocytoma among Alaska Native children 
compared to US white children. Smith et al.28 reported that the lower incidence of in ALL in 
African American children was largely due to the lack of a pronounced age peak in this 
group. Moreover, Linet, Wacholder, and Zahm29 reported that the low incidence in African 
American children may be due to genetic or environmental factors. Swensen, Ross, 
Severson, Pollock, and Robison19 reported that there were significant differences between 
white and African American children with ALL regarding socioeconomic status. Regarding 
racial/ethnic differences for astrocytoma, Gurney et al.23 stated that differences between 
race/ethnicities may be due to access to care. Improvements in the quality of diagnostic tests, 
such as Magnetic Resonance Imaging, and improved surgical diagnostic techniques have 
increased the incidence of childhood brain tumors through earlier diagnosis. Children 
without access to these diagnostic techniques may be diagnosed later typically resulting in 
lower survival.30 Regarding Hodgkin lymphoma, Percy et al.24 reported that the age-specific 
incidence for white and African American children was similar among children under 10 
years, but a higher incidence among white compared to African American in older children 
(10-19 years), which we were unable to confirm due to small numbers.
Regarding age, survival for ALL was lowest among children under 1 year of age in 
Oklahoma and the US, which is almost entirely due to a rearrangement of 11q23 (MLL 
gene), which in more common in infants compared to older children.31 Metzger et al.32 
reported that adolescents with Hodgkin's lymphoma tend to have poorer survivability than 
younger children. Bleyer et al.33 reported that adolescents aged 15-19 were less likely to be 
included in cancer trials than children from 10-14 years, which may adversely affect their 
outcome, since participating in trials has been shown to have many benefits, including better 
survival. Because Hodgkin's lymphoma is more common in adolescence, participation in 
cancer trials is an important factor for this cancer.33 The authors stated that approximately 
75% of adolescents aged 15-19 were more often treated in adult cancer centers where 
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participation in clinical trials is lower than that in children's centers. Possible reasons for 
lower participation were the difficulty of treating adolescent cancers in an adult center where 
pediatric clinical trials may not be available, along with participating in a clinical trial and 
reluctance of both parents and adolescents to be treated at a childhood center.33
There were several possible reasons for apparent differences in survival for the selected 
childhood cancers between race/ethnicity groups. One is that the small number of cases in 
each age group and race/ethnicity, which decreased the precision of the estimate. Another 
could be due to unequal access to care and quality of care among minority races/ethnicities. 
Studies have observed that racial minorities, including African Americans, AI/ANs, and 
Hispanics, had lower survival, which may be due to access to care and adherence to therapy 
over a long period of time.34-36 Specifically for ALL, African American children, especially 
those between years 1 and 9, tend to have lower survivability due to poor prognostic 
factors.34,36,37 Metzger et al.32 observed that African American children had similar clinical 
characteristics of Hodgkin lymphoma compared to white children, but lower socioeconomic 
status. While five-year relative survival was similar between the race/ethnic groups, 
treatment failure was higher among African American children compared to white 
children.32 Evidence is limited regarding survival differences by race/ethnicity of 
astrocytoma, with one study observing no differences.38
An advantage of this study was the ability to include cases of childhood cancer from high 
quality population-based registries in Oklahoma and the US. Furthermore, Oklahoma has a 
high proportion of AI/ANs compared to the US (9.0% v. 1.2%, respectively), which allowed 
us to describe the three selected childhood cancers among this underrepresented group.39 
This was also the first descriptive study of childhood cancer epidemiology in Oklahoma, 
which allows for hypothesis generating for future studies.
One of the limitations of this study was the small sample size. Even combining 16 years of 
data in Oklahoma, we were unable to analyze the majority of childhood cancer types by age 
and race/ethnicity or examine time trends. The rarity of childhood cancer was evidenced by 
the wide 95% CIs for survival estimates by age and race/ethnicity, which may result in 
failing to detect true differences in the survival proportions between Oklahoma and the US.
Another limitation of this study was our assumption regarding follow-up time in the registry. 
OCCR regularly conducts follow-up of those included in the cancer registry and links with 
the NDI to determine vital status. However, this linkage was not completed each year at 
OCCR, but the majority of cases were updated with Oklahoma Mortality Data and the Social 
Security Death Index to identify those who are deceased. This may artificially inflate 
survival in more recent years and trends should be closely monitored. Furthermore, we 
assumed that children were alive through the end of the study period if they were not 
classified as deceased, but some misclassification may be present due to reporting delays, 
which may result in an overestimate of survival. However, the presumed alive methodology 
used by the OCCR results in similar survival estimates as SEER data, which conducts active 
follow-up.40,41
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In recent years, much research has been conducted on the epidemiology of childhood cancer, 
especially at national and international levels. Little research has been done, however, on the 
incidence or survival of childhood cancer at state levels and none focused exclusively on 
Oklahoma. While there are many obstacles to studying such a rare disease, it is important to 
understand the burden of childhood cancer in Oklahoma in order to better understand risk 
factors, etiology, and the overall health of the state, which may lead to future prevention 
strategies.
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Figure 1. Five-year observed survival (95% confidence intervals) for acute lymphoblastic 
leukemia, astrocytoma, and Hodgkin lymphoma by age group in Oklahoma and the US, 
1997-2012
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Table 1
Average annual age-adjusted incidence rates per million person-years of childhood 
cancers and 95% confidence intervals from 1997-2012a
Oklahomab SEERc
Cancer Type N Incidence Rate (95% CI) N Incidence Rate (95% CI)
Totald 2797 171.7 (165.4, 178.1) 30506 168.9 (167.0, 170.8)
I Leukemias, myeloproliferative & myelodysplastic diseases 735 45.4 (42.1, 48.7) 8212 45.4 (44.4, 46.4)
 I(a) Lymphoid leukemias 524 32.5 (29.7, 35.2) 6271 34.7 (33.8, 35.5)
 I(b) Acute myeloid leukemias 139 8.5 (7.1, 9.9) 1506 8.3 (7.9, 8.8)
 I(c) Chronic myeloproliferative diseases 34 2.1 (1.4, 2.8) 198 1.1 (1.0, 1.3)
 I(d) Myelodysplastic syndrome/other myeloproliferative 11 0.7 (0.3, 1.1) 52 0.3 (0.2, 0.4)
 I(e) Unspecified and other specified leukemias 27 1.6 (1.0, 2.3) 185 1.0 (0.9, 1.2)
II Lymphomas and reticuloendothelial neoplasms 361 22.1 (19.8, 24.4) 4376 24.4 (23.7, 25.1)
 II(a) Hodgkin lymphomas 179 10.8 (9.3, 12.4) 2158 12.0 (11.5, 12.5)
 II(b) Non-Hodgkin lymphomas (except Burkitt lymphoma) 111 6.8 (5.6, 8.1) 1600 8.9 (8.5, 9.4)
 II(c) Burkitt lymphoma 38 2.4 (1.6, 3.2) 435 2.4 (2.2, 2.7)
 II(d) Miscellaneous lymphoreticular neoplasms 22 1.3 (0.8, 1.9) 118 0.6 (0.5, 0.8)
 II(e) Unspecified lymphomas 11 0.7 (0.3, 1.1) 65 0.4 (0.3, 0.5)
III CNS and misc intracranial and intraspinal neoplasms 563 34.8 (31.9, 37.7) 5145 28.5 (27.8, 29.3)
 III(a) Ependymomas and choroid plexus tumor 46 2.8 (2.0, 3.7) 457 2.5 (2.3, 2.8)
I II(b) Astrocytomas 210 13.0 (11.3, 14.8) 2523 14.0 (13.5, 14.6)
 III(c) Intracranial and intraspinal embryonal tumors 113 7.0 (5.7, 8.3) 1138 6.3 (5.9, 6.7)
 III(d) Other gliomas 61 3.8 (2.8, 4.7) 900 5.0 (4.7, 5.4)
 III(e) Other specified intracranial/intraspinal neoplasms 97 6.0 (4.8, 7.1) 81 0.4 (0.4, 0.6)
 III(f) Unspecified intracranial and intraspinal neoplasms 36 2.2 (1.5, 3.0) 46 0.3 (0.2, 0.3)
IV Neuroblastoma and other peripheral nervous cell tumors 127 7.8 (6.4, 9.1) 1443 7.9 (7.5, 8.3)
 IV(a) Neuroblastoma and ganglioneuroblastoma 123 7.5 (6.2, 8.8) 1396 7.6 (7.2, 8.0)
 IV(b) Other peripheral nervous cell tumors <5 N/Ae 47 0.3 (0.2, 0.3)
V Retinoblastoma 33 2.0 (1.3, 2.7) 624 3.4 (3.1, 3.7)
VI Renal tumors 124 7.6 (6.3, 9.0) 1141 6.3 (5.9, 6.6)
 VI(a) Nephroblastoma/other nonepithelial renal tumorsf 115 7.1 (5.8, 8.4) 1035 5.7 (5.3, 6.0)
 VI(b) Renal carcinomas 5 0.3 (0.0, 0.6) 105 0.6 (0.5, 0.7)
 VI(c) Unspecified malignant renal tumors <5 N/Ae <5 N/Ae
VII Hepatic tumors 44 2.7 (1.9, 3.5) 449 2.5 (2.2, 2.7)
 VII(a) Hepatoblastoma 28 1.7 (1.1, 2.3) 329 1.8 (1.6, 2.0)
 VII(b) Hepatic carcinomas 15 0.9 (0.5, 1.4) 117 0.7 (0.5, 0.8)
 VII(c) Unspecified malignant hepatic tumors <5 N/Ae <5 N/Ae
VIII Malignant bone tumors 147 9.0 (7.6, 10.5) 1532 8.5 (8.1, 9.0)
 VIII(a) Osteosarcomas 78 4.8 (3.7, 5.9) 889 5.0 (4.6, 5.3)
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Oklahomab SEERc
Cancer Type N Incidence Rate (95% CI) N Incidence Rate (95% CI)
 VIII(b) Chondrosarcomas <5 N/Ae 62 0.3 (0.3, 0.4)
 VIII(c) Ewing tumor and related sarcomas of bone 54 3.3 (2.4, 4.2) 482 2.7 (2.5, 2.9)
 VIII(d) Other specified malignant bone tumors <5 N/Ae 78 0.4 (0.3, 0.5)
 VIII(e) Unspecified malignant bone tumors 8 0.5 (0.2, 0.8) 21 0.1 (0.1, 0.2)
IX Soft tissue and other extraosseous sarcomas 210 12.8 (11.1, 14.6) 2189 12.1 (11.6, 12.7)
 IX(a) Rhabdomyosarcomas 67 4.1 (3.1, 5.1) 819 4.5 (4.2, 4.9)
 IX(b) Fibrosarcomas, peripheral nerve & other fibrous 40 2.4 (1.7, 3.2) 260 1.4 (1.3, 1.6)
 IX(c) Kaposi sarcoma 0 N/Ae 11 0.1 (0.0, 0.1)
 IX(d) Other specified soft tissue sarcomas 88 5.3 (4.2, 6.5) 888 4.9 (4.6, 5.3)
 IX(e) Unspecified soft tissue sarcomas 15 0.9 (0.5, 1.4) 211 1.2 (1.0, 1.3)
X Germ cell & trophoblastic tumors & neoplasms of gonads 153 9.3 (7.8, 10.7) 2203 12.2 (11.7, 12.7)
 X(a) Intracranial & intraspinal germ cell tumors 22 1.4 (0.8, 1.9) 342 1.9 (1.7, 2.1)
 X(b) Extracranial & extragonadal germ cell tumors 25 1.5 (0.9, 2.1) 297 1.6 (1.4, 1.8)
 X(c) Malignant gonadal germ cell tumors 91 5.5 (4.4, 6.6) 1447 8.0 (7.6, 8.5)
 X(d) Gonadal carcinomas 10 0.6 (0.2, 1.0) 84 0.5 (0.4, 0.6)
 X(e) Other and unspecified malignant gonadal tumors 5 0.3 (0.0, 0.6) 33 0.2 (0.1, 0.3)
XI Other malignant epithelial neoplasms and melanomas 245 14.9 (13.0, 16.7) 3032 16.9 (16.3, 17.5)
 XI(a) Adrenocortical carcinomas 6 0.4 (0.1, 0.7) 47 0.3 (0.2, 0.3)
 XI(b) Thyroid carcinomas 66 4.0 (3.0, 5.0) 1253 7.0 (6.6, 7.4)
 XI(c) Nasopharyngeal carcinomas 15 0.9 (0.5, 1.4) 85 0.5 (0.4, 0.6)
 XI(d) Malignant melanomas 91 5.5 (4.4, 6.7) 885 4.9 (4.6, 5.3)
 XI(e) Skin carcinomas <5 N/Ae 16 0.1 (0.1, 0.1)
 XI(f) Other and unspecified carcinomas 65 3.9 (3.0, 4.9) 746 4.2 (3.9, 4.5)
XII Other and unspecified malignant neoplasms 28 1.7 (1.1, 2.4) 98 0.5 (0.4, 0.7)
 XII(a) Other specified malignant tumors <5 N/Ae 57 0.3 (0.2, 0.4)
 XII(b) Other unspecified malignant tumors 26 1.6 (1.0, 2.2) 41 0.2 (0.2, 0.3)
aChildhood cancers classified by the International Classification of Childhood Cancers15
bAge-adjusted incidence rates per 1 million, based on OCCR data
cAge-adjusted incidence rates per 1 million, based on SEER data42
d
Total includes children not classified by ICCC
e
Fewer than 5 cases observed, data suppressed for confidentiality and stability reasons
fAlso known as Wilms' Tumor
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Table 2
Age-specific incidence rate per million for acute lymphoblastic leukemia, astrocytoma, 
and Hodgkin lymphoma in Oklahoma and the US, 1997-2012, ages 0-19
Age Group Oklahoma Incidence Ratea SEER Incidence Ratea Rate Ratio (95% CI)
Acute Lymphoblastic Leukemia
 <1 year 19.9 (10.1, 29.6) 21.3 (18.3, 24.3) 0.93 (0.56, 1.55)
 1 to 4 year 69.1 (60.0, 78.3) 77.5 (74.6, 80.4) 0.89 (0.78, 1.02)
 5 to 9 years 37.3 (31.2, 43.3) 34.7 (33.0, 36.5) 1.07 (0.91, 1.27)
 10 to 14 years 17.1 (13.0, 21.1) 21.6 (20.2, 22.9) 0.79 (0.62, 1.01)
 15 to 19 years 17.5 (13.5, 21.5) 17.5 (16.3, 18.8) 1.00 (0.79, 1.27)
Astrocytoma
 <1 year 8.7 (2.3, 15.1) 12.6 (10.3, 14.9) 0.69 (0.32, 1.48)
 1 to 4 year 14.6 (10.4, 18.8) 18.1 (16.7, 19.5) 0.81 (0.60, 1.09)
 5 to 9 years 15.7 (11.8, 19.6) 15.1 (13.9, 16.2) 1.04 (0.80, 1.35)
 10 to 14 years 11.4 (8.1, 14.7) 13.7 (12.6, 14.7) 0.83 (0.62, 1.12)
 15 to 19 years 11.6 (8.3, 14.8) 10.4 (9.5, 11.3) 1.11 (0.83, 1.50)
Hodgkin Lymphoma
 <1 year N/Ab N/Ab N/Ab
 1 to 4 year N/Ab 0.9 (0.6, 1.2) N/Ab
 5 to 9 years 3.3 (1.5, 5.1) 4.3 (3.7, 4.9) 0.76 (0.43, 1.34)
 10 to 14 years 9.2 (6.2, 12.1) 12.1 (11.1, 13.2) 0.75 (0.54, 1.05)
 15 to 19 years 30.3 (25.0, 35.5) 30.5 (28.9, 32.1) 0.99 (0.83, 1.19)
a
Incidence rates are unadjusted and per 1 million population
b
Rates with fewer than 5 cases suppressed due to confidentiality and stability reasons
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Table 3
Age-adjusted incidence rate per million and 95% confidence intervals of for acute 
lymphoblastic leukemia, astrocytoma, and Hodgkin lymphoma by race/ethnicity in 
Oklahoma and the US, 1997-2012, ages 0-19
Oklahoma Incidence Ratea (95% 
CI)
SEER Incidence Ratea (95% CI) Rate Ratio (95% CI)
Acute Lymphoblastic Leukemia
 White NHb 32.0 (28.6, 35.5) 34.1 (32.8, 35.3) 0.94 (0.84, 1.05)
 African American NH 17.7 (11.4, 24.0) 16.7 (15.0, 18.4) 1.06 (0.73, 1.54)
 American Indian/Alaska Native NH 40.3 (31.4, 49.2) 33.1 (26.3, 39.9) 1.22 (0.90, 1.65)
 Hispanic 43.9 (34.2, 53.6) 44.5 (42.7, 46.3) 0.99 (0.79, 1.24)
Astrocytoma
 White NH 14.0 (11.7, 16.3) 17.7 (16.8, 18.6) 0.79 (0.67, 0.94)
 African American NH 10.1 (5.3, 14.8) 11.2 (9.8, 12.6) 0.90 (0.55, 1.47)
 American Indian/Alaska Native NH 11.0 (6.4, 15.6) 9.6 (5.9, 13.2) 1.15 (0.65, 2.03)
 Hispanic 14.5 (8.8, 20.2) 10.3 (9.5, 11.2) 1.41 (0.94, 2.11)
Hodgkin Lymphoma
 White NH 11.7 (9.6, 13.8) 14.7 (13.9, 15.5) 0.83 (0.67, 1.02)
 African American NH 5.4 (1.9, 8.9) 10.1 (8.8, 11.4) 0.50 (0.21, 1.23)
 American Indian/Alaska Native NH 10.4 (5.9, 14.9) 4.7 (2.1, 7.2) 3.78 (1.48, 9.67)
 Hispanic 11.5 (6.4, 16.5) 9.9 (9.0, 10.7) 1.39 (0.76, 2.54)
aAge-adjusted incidence rates per 1 million population
bNH: non-Hispanic
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Table 4
Five-year observed survival proportions and 95% confidence intervals for childhood 
cancers in the US and Oklahoma from 1997-2012, ages 0-19a
Cancer Type Oklahomab SEERc
Totald 77.0 (75.2, 78.9) 80.6 (80.2, 81.0)
I Leukemias, myeloproliferative & myelodysplastic diseases 75.9 (72.3, 79.6) 79.7 (78.9, 80.5)
 I(a) Lymphoid leukemias 85.2 (81.7, 88.8) 85.2 (84.4, 86.0)
 I(b) Acute myeloid leukemias 47.2 (37.7, 56.7) 58.5 (56.3, 60.7)
 I(c) Chronic myeloproliferative diseases 71.4 (47.8, 95.1) 81.5 (76.8, 86.2)
 I(d) Myelodysplastic syndrome/other myeloproliferative N/Ae 58.4 (47.2, 69.6)
 I(e) Unspecified and other specified leukemias 68.0 (49.7, 86.3) 64.3 (58.2, 70.4)
II Lymphomas and reticuloendothelial neoplasms 85.1 (80.9, 89.3) 89.4 (88.6, 90.2)
 II(a) Hodgkin lymphomas 91.7 (86.9, 96.4) 95.5 (94.7, 96.3)
 II(b) Non-Hodgkin lymphomas (except Burkitt lymphoma) 74.7 (65.4, 84.0) 82.1 (80.3, 83.9)
 II(c) Burkitt lymphoma 87.9 (76.7, 99.0) 87.5 (84.8, 90.2)
 II(d) Miscellaneous lymphoreticular neoplasms 77.8 (58.6, 97.0) 84.4 (79.5, 89.3)
 II(e) Unspecified lymphomas 88.9 (68.3, 100.0) 78.1 (68.9, 87.3)
III CNS and misc intracranial and intraspinal neoplasms 71.7 (67.2, 76.1) 72.5 (71.5, 73.5)
 III(a) Ependymomas and choroid plexus tumor 80.0 (65.7, 94.3) 73.1 (69.6, 76.6)
 III(b) Astrocytomas 71.6 (64.5, 78.7) 83.1 (81.9, 84.3)
 III(c) Intracranial and intraspinal embryonal tumors 65.9 (56.0, 75.8) 62.7 (60.3, 65.1)
 III(d) Other gliomas 51.0 (37.3, 64.7) 57.9 (55.2, 60.6)
 III(e) Other specified intracranial/intraspinal neoplasms 89.4 (80.5, 98.2) 67.7 (58.9, 76.5)
 III(f) Unspecified intracranial and intraspinal neoplasms 95.2 (86.1, 100.0) 38.1 (26.3, 49.9)
IV Neuroblastoma and other peripheral nervous cell tumors 58.4 (48.8, 68.0) 73.7 (71.7, 75.7)
 IV(a) Neuroblastoma and ganglioneuroblastoma 58.2 (48.4, 67.9) 73.6 (71.6, 75.6)
 IV(b) Other peripheral nervous cell tumors N/Ae 76.2 (64.8, 87.6)
V Retinoblastoma 92.9 (83.3, 100.0) 96.9 (95.7, 98.1)
VI Renal tumors 79.1 (70.8, 87.5) 88.1 (86.5, 89.7)
 VI(a) Nephroblastoma/other nonepithelial renal tumorsf 77.4 (68.4, 86.3) 89.1 (87.5, 90.7)
 VI(b) Renal carcinomas N/Ae 75.1 (66.9, 83.3)
 VI(c) Unspecified malignant renal tumors N/Ae N/Ae
VII Hepatic tumors 58.1 (40.7, 75.4) 62.3 (58.2, 66.4)
 VII(a) Hepatoblastoma 59.1 (38.5, 79.6) 72.5 (68.0, 77.0)
 VII(b) Hepatic carcinomas 50.0 (15.3, 84.7) 37.0 (29.2, 44.8)
 VII(c) Unspecified malignant hepatic tumors N/Ae N/Ae
VIII Malignant bone tumors 69.2 (60.4, 77.9) 67.9 (65.9, 69.9)
 VIII(a) Osteosarcomas 63.6 (50.9, 76.4) 65.6 (62.9, 68.3)
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Cancer Type Oklahomab SEERc
 VIII(b) Chondrosarcomas N/Ae 93.9 (88.8, 99.0)
 VIII(c) Ewing tumor and related sarcomas of bone 74.4 (60.7, 88.1) 66.4 (62.7, 70.1)
 VIII(d) Other specified malignant bone tumors N/Ae 80.1 (72.5, 87.7)
 VIII(e) Unspecified malignant bone tumors 62.5 (28.9, 96.1) 75.3 (61.2, 89.4)
IX Soft tissue and other extraosseous sarcomas 76.5 (69.3, 83.6) 71.2 (69.4, 73.0)
 IX(a) Rhabdomyosarcomas 71.4 (57.8, 85.1) 63.8 (61.1, 66.5)
 IX(b) Fibrosarcomas, peripheral nerve & other fibrous 73.9 (56.0, 91.9) 76.5 (71.8, 81.2)
 IX(c) Kaposi sarcoma N/Ae N/Ae
 IX(d) Other specified soft tissue sarcomas 81.0 (71.2, 90.7) 77.7 (75.3, 80.1)
 IX(e) Unspecified soft tissue sarcomas 75.0 (45.0, 100.0) 68.3 (62.6, 74.0)
X Germ cell & trophoblastic tumors & neoplasms of gonads 89.0 (83.1, 94.9) 90.4 (89.2, 91.6)
 X(a) Intracranial & intraspinal germ cell tumors 82.4 (64.2, 100.0) 85.8 (82.5, 89.1)
 X(b) Extracranial & extragonadal germ cell tumors 86.7 (69.5, 100.0) 81.8 (77.9, 85.7)
 X(c) Malignant gonadal germ cell tumors 96.8 (92.4, 100.0) 94.7 (93.7, 95.7)
 X(d) Gonadal carcinomas 70.0 (41.6, 98.4) 73.2 (63.8, 82.6)
 X(e) Other and unspecified malignant gonadal tumors 60.0 (17.1, 100.0) 77.5 (65.2, 89.8)
XI Other malignant epithelial neoplasms and melanomas 88.3 (83.5, 93.1) 91.4 (90.4, 92.4)
 XI(a) Adrenocortical carcinomas N/Ae 56.6 (42.3, 70.9)
 XI(b) Thyroid carcinomas 100.0 (100.0, 100.0) 98.6 (98.0, 99.2)
 XI(c) Nasopharyngeal carcinomas 66.7 (40.0, 93.3) 86.9 (80.8, 93.0)
 XI(d) Malignant melanomas 98.6 (95.8, 100.0) 94.6 (93.4, 95.8)
 XI(e) Skin carcinomas N/Ae 100.0 (100.0, 100.0)
 XI(f) Other and unspecified carcinomas 72.5 (58.7, 86.3) 77.2 (74.5, 79.9)
XII Other and unspecified malignant neoplasms 80.0 (64.3, 95.7) 80.7 (74.0, 87.4)
 XII(a) Other specified malignant tumors N/Ae 80.7 (72.5, 88.9)
 XII(b) Other unspecified malignant tumors 78.3 (61.4, 95.1) 80.3 (68.7, 91.9)
aChildhood cancers classified by the International Classification of Childhood Cancers15
b
Based on OCCR data
c
Based on SEER data42
d
Total includes children not classified by ICCC
e
Fewer than 5 cases observed, data suppressed for confidentiality and stability reasons
fAlso known as Wilms' Tumor
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Table 5
Five-year observed survival (95% confidence intervals) for acute lymphoblastic leukemia, 
astrocytoma, and Hodgkin lymphoma by race/ethnicity for Oklahoma, 1997-2012, ages 
0-19
ALL Astrocytoma Hodgkin Lymphoma
Race/Ethnicity Percent (95% CI) Percent (95% CI) Percent (95% CI)
White NHa 86.0 (81.6, 90.3) 73.4 (65.1, 81.7) 91.8 (86.3, 97.2)
African American NH 70.8 (52.6, 89.0) 50.0 (23.8, 76.2) 83.3 (53.5, 100.0)
American Indian/Alaska Native NH 82.0 (72.3, 91.6) 87.5 (71.3, 100.0) 94.4 (83.9, 100.0)
Hispanic 92.0 (84.5, 99.5) 62.5 (38.8, 86.2) 100.0 (100.0, 100.0)
aNH: non-Hispanic
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